Please find attached the Fourth Quarter Report 2025 for SoftOx Solutions AS.
Click here for more information
© Oslo Bors ASA, source Oslo Stock Exchange
SoftOx Solutions AS: Fourth Quarter Report 2025
Earlier from SoftOx Solutions AS
- SoftOx Solutions AS: First Subject Dosed in Combined Phase 2a Dose-Escalation and Proof-of-Concept Trial (SIS-03)
- SoftOx Solutions AS: Danish Medicines Agency Approves Phase 2a Trial for SoftOx Inhalation Solution
- SoftOx Solutions AS: Third Quarter Report 2025
- SoftOx Solutions AS: GMP Drug Substance Successfully Manufactured - Key Milestone for CF and EDF Clinical Programs
- SoftOx Solutions AS: SoftOx submits Phase 1 Clinical Trial Application under the European Defence Fund (EDF) Program
Later from SoftOx Solutions AS
- SoftOx Solutions AS: New Share Capital
- SoftOx Solutions AS: Annual Report 2025
- SoftOx Solutions AS: FIRST PARTICIPANT ENROLLED IN BIODEFENCE-FOCUSED SIS-02 PHASE 1 CLINICAL STUDY
- SoftOx Solutions AS: SIS-03 DOSE-ESCALATION PHASE COMPLETED AND INITIATION OF PROOF-OF-CONCEPT PHASE
- SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited
Follow SoftOx Solutions AS into a list and get an email when it puts out news.
Follow SoftOx Solutions AS